Entera Bio Ltd. Enterprise Value

Enterprise Value of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Enterprise Value growth rates and interactive chart. Calculated as market cap + net debt. A company with a market cap of $1 billion and net cash of $500 million will have an enterprise value of $500 million. Not applicable to financial companies, due to the structure of cash on their balance sheet.

Highlights and Quick Summary

Current Enterprise Value of Entera Bio Ltd. is $10.9 Million (as of December 30, 2019)
  • Enterprise Value for the quarter ending June 29, 2020 was $23.9 Million (a -0.34% decrease compared to previous quarter)
  • Year-over-year quarterly Enterprise Value decreased by -1.62%
  • Annual Enterprise Value for 2019 was $10.9 Million (a -72.83% decrease from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Enterprise Value of Entera Bio Ltd.

Most recent Enterprise Valueof ENTX including historical data for past 10 years.

Interactive Chart of Enterprise Value of Entera Bio Ltd.

Entera Bio Ltd. Enterprise Value for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $23.86 $23.95
2019 $10.93 $24.26 $32.61 $10.93
2018 $40.23 $40.23

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.